Menu
Menu
We’re thrilled to welcome Seguros SURA Colombia to the SOPHiA GENETICS community as they adopt MSK-ACCESS® powered by SOPHiA DDM™ to advance their precision oncology research initiatives.
As one of Latin America’s leading healthcare organizations, Seguros SURA Colombia is recognized for its commitment to driving innovation and research that strengthens the healthcare ecosystem. By implementing this cutting-edge liquid biopsy solution for research purposes, SURA is empowering its teams to generate insights that will help advance precision medicine initiatives in Colombia and across the region.
“We are excited to integrate MSK-ACCESS® powered by SOPHiA DDM™ into our Omics Sciences Center. This platform will enable us to deepen our understanding of cancer biology and contribute to the growth of precision medicine in Colombia.” Said Carlos Andrés Agudelo, Manager of the Biosciences Center, Seguros SURA Colombia
At SOPHiA GENETICS, our mission is to democratize data-driven medicine worldwide by giving healthcare and research institutions access to powerful, AI-enabled analytics that transform complex data into meaningful insights. We’re proud to partner with Seguros SURA Colombia as they take this important step toward advancing precision oncology research across the region.
Here’s to expanding access to innovation and accelerating research for better outcomes.
Learn more about MSK-ACCESS® powered with SOPHiA DDM™: https://www.sophiagenetics.com/sophia-ddm-for-genomics/liquid-biopsy/msk-access/
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
